ALNY
ALNYLAM PHARMACE
Health Care·Biotechnology·UNITED STATES
$266.11
MCap $35.6B
as of 2026-09-04
Total
D4w
Fund
C4w
Quant
E10w
Price
▲ Up▼ Down━ MA30━ MA100━ Mean┄ U┄ L
MIDOS % pane · green > 90 long zone · red < 10 short zone · reference lines at 10 / 90
MIDOS SI
as of 2026-09-04
MIDOS SI
+0.20
Sentiment 28.9%
−3 oversold0+3 overbought
Signal
NEUTRAL
Actual
$266.11
Adaptive Mean
$264.57
+1.54 vs mean
Adaptive σ
3.93
MIDOS BB
$256.71 – $272.42
center ± 2σ adaptive
Fundamental Factors (Sector-Relative Z)
as of 2026-09-04
Composite Z
+1.01
ROE
96.6%
Z +1.68
Rev Gr
66.9%
Z +0.51
EPS Gr
—
Z +0.07
OPM Gr
20.0%
Z +4.15
FCF Yld
0.8%
Z +0.17
EPS Surp
-0.1%
Z +0.35
EPS 3mo Δ
-20.2%
Z +0.12
Fwd P/E
21.14
Z —
PEGY
N/A
growth + yield ≤ 0
Momentum (Risk-Adjusted Alpha)
as of 2026-09-04
Q3M
-1.40
Q6M
-2.88
Q12M
-6.49
MA 30/100
0.854
Bearish (MA30 < MA100)
α (Jensen)
-0.1638
β (12M)
0.33
σ (12M)
0.468
Momentum inflection: Q3M > Q12M
Divergence — Fundamentals vs Momentum
Z Percentile
98%
Q Percentile
8%
Divergence
+89.9
Tier
RELOAD — WATCH
Fundamentals well ahead of momentum. Strong reload candidate when momentum inflects.
Kirkpatrick RS & Persistence
RS
-29.7
RS Pctl
16%
RS Decile
D2
Persistence
4w
at grade D
Options / OI Analysis
No options or Williams data available for this ticker.